2 recruiting. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
| Phase 2 | 1 | Recruiting 1 |
Follow UB-VV400: new trials by email Literature Review of UB-VV400 trials Research Report on UB-VV400
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies UB-VV400, Rapamycin (sirolimus) - Lymphoma, B Cell, Lymphoma Non-Hodgkin | Phase 1 / Phase 2 | Recruiting | Umoja Biopharma | 274 | 2026-09-01 | 2026-10-09 |
| UB-VV400 in Combination With Rapamycin in Relapsed or Refractory B-cell Malignancies UB-VV400, Rapamycin - Large B-cell Lymphoma | Phase 1 | Recruiting | Nanjing IASO Biotechnology Co., Ltd. | 70 | 2025-04-11 | 2025-09-18 |
Lymphoma, B-Cell (1) · Lymphoma, Large B-Cell, Diffuse (1) · Lymphoma, Non-Hodgkin (1) · Recurrence (1)
Nanjing IASO Biotechnology Co., Ltd. (1) · Umoja Biopharma (1)
China (1) · United States (1)
Lei Fan (1) · Luke Walker, MD (1)